Fingolimod in Relapsing Pediatric Multiple Sclerosis
The PARADIGMS Trial in Pediatric Multiple Sclerosis
Pediatric Multiple Sclerosis: Treatment Overview
Pediatric Multiple Sclerosis: Treatment Sequencing and Monitoring
Pediatric MS: Support for Patients and Caregivers
Navigating Through Pediatric Multiple Sclerosis
Pediatric MS: Treatment Guidelines
Diagnosing Pediatric Multiple Sclerosis
Symptoms of Pediatric Multiple Sclerosis
Pathogenesis of Pediatric Multiple Sclerosis
The Etiology of Multiple Sclerosis
FDA Expands Deflazacort Indication for Duchenne Muscular Dystrophy
The FDA has approved an sBLA for deflazacort that expands the label to patients aged 2 to 5 with Duchenne muscular dystrophy.
Development of Oral CGRP Molecule Inhibitors for Acute Migraines
Effect of CGRP Inhibitors on Patients With Cluster Headaches
Dosage and Administration of Anti-CGRP Monoclonal Antibodies for Migraine
Optimizing Patient Management to Help Reduce Migraine Days
Cumulative Benefit With Anti-CGRPs in Real-World Experience
Response to CGRP Inhibitors: Refractory Migraine & Drug Overuse
Migraine: Safety & Efficacy of Anti-CGRPs and Patient Selection
Risk of CV Events With Anti-CGRPs in Patients With Migraine
Mechanism of Action of Antibodies in Migraine Therapy
Hormone Therapy to Reduce Severity of Menstrual Migraines
Migraine: Mechanism of Action of OnabotulinumtoxinA
Preventing Chronic Migraine Using OnabotulinumtoxinA
Personal Approach to Oral Preventive Therapy for Migraine
A Historic Perspective on Preventive Therapy for Migraine
SRK-015 Shows Promise for SMA With Robust Early Phase Results
The highly specific myostatin activation inhibitor is expected to enter phase 2 study in spinal muscular atrophy, according to SRK-015’s manufacturer, Scholar Rock.
FDA Accepts Ozanimod NDA for Treatment of Relapsing Forms of Multiple Sclerosis
The FDA has set a PDUFA date of March 25, 2020.
Amy Sullivan, PysD: Team-Based Approach to MS
The director of Behavioral Medicine at the Mellen Center for MS Treatment and Research at the Cleveland Clinic spoke about the importance of caring for patients with MS by using a team-based approach.
FDA Clears Zilucoplan IND for Immune-Mediated Necrotizing Myopathy
Zilucoplan, also being developed for generalized myasthenia gravis, is expected to enter into a phase 2 clinical trial in IMNM in the second half of 2019, according to Ra Pharma.
